long intergenic non-protein coding RNA 2323Genealiases: []
Q-omics provides the consensus-scored LINC02323 profile across patient tissues and cancer cell-line models. LINC02323 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, LINC02323 is differentially expressed in 14, with the highest sampling consensus in LUAD. Additionally, LINC02323 RNA expression shows 10,837 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight KIRC, LUAD, and BRCA as cancer lineages where LINC02323 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC02323 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC02323 survival associations across molecular data types. LINC02323 RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC02323 RNA expression–survival associations across cancer types. High LINC02323 expression shows unfavorable associations in KIRC, LUAD, ACC and PAAD, but favorable associations in UCS and UVM. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for LINC02323 RNA expression.
This table summarizes LINC02323 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for LINC02323. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC02323 shows lower tumor expression in KIRC and higher tumor expression in LUAD, HNSC, COAD, LUSC and PAAD. The LUAD box plot shows higher LINC02323 RNA expression in tumor versus normal tissue (log2 FC = +0.913, t-test p < 0.001).
This table shows molecular features associated with LINC02323 in patient tissues and cancer cell lines. In patient samples, LINC02323 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set.
